Show simple item record

dc.creatorRizzo, Manfredi
dc.creatorVekić, Jelena
dc.creatorKoulouris, Spyridon
dc.creatorZeljković, Aleksandra
dc.creatorJelić-Ivanović, Zorana
dc.creatorSpasojević-Kalimanovska, Vesna
dc.creatorRini, Giovam Battista
dc.creatorSakellariou, Dimitrios
dc.creatorPastromas, Socrates
dc.creatorMikhailidis, Dimitri P.
dc.creatorManolis, Antonis S.
dc.date.accessioned2019-09-02T11:21:44Z
dc.date.available2019-09-02T11:21:44Z
dc.date.issued2010
dc.identifier.issn0003-3197
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/1398
dc.description.abstractRosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbAlc] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased (+1.4%, P = .034), with less small, dense LDL-IIIA (-25.1%, P = .018). Postprandially, larger HDL-2b reduced (-8.7%, P = .006) and smaller HDL-3b increased (+12.2%, P = .05), without any effects on HDL size. Rosiglitazone led to antiatherogenic changes in LDL size and subclasses, with proatherogenic changes in HDL subclasses, despite no effects on plasma lipids. Their clinical relevance remains to be established.en
dc.publisherSage Publications Inc, Thousand Oaks
dc.relationinfo:eu-repo/grantAgreement/MESTD/MPN2006-2010/145036/RS//
dc.rightsrestrictedAccess
dc.sourceAngiology
dc.subjectRosiglitazoneen
dc.subjectdiabetesen
dc.subjectlow-density lipoproteinsen
dc.subjecthigh-density lipoproteinsen
dc.subjectsizeen
dc.subjectsubclassesen
dc.titleEffects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetesen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractКоулоурис, Спyридон; Спасојевић-Калимановска, Весна; Зељковић, Aлександра; Риззо, Манфреди; Манолис, Aнтонис С.; Рини, Гиовам Баттиста; Сакеллариоу, Димитриос; Пастромас, Соцратес; Микхаилидис, Димитри П.; Векић, Јелена; Јелић-Ивановић, Зорана;
dc.citation.volume61
dc.citation.issue6
dc.citation.spage584
dc.citation.epage590
dc.citation.other61(6): 584-590
dc.citation.rankM23
dc.identifier.wos000279760800011
dc.identifier.doi10.1177/0003319710366431
dc.identifier.pmid20462890
dc.identifier.scopus2-s2.0-77955033179
dc.identifier.rcubconv_2326
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record